Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Female
Interventions: DRUG: 99mTc-ADAPT6|DRUG: 99mTc-DARPinG3
Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborators: Uppsala University